ALLR NASDAQ
Allarity Therapeutics, Inc.
1W: +5.0%
1M: -5.0%
3M: -20.7%
YTD: -19.3%
1Y: -33.8%
3Y: -99.8%
$0.92
+0.00 (+0.54%)
Weekly Expected Move ±10.4%
$1
$1
$1
$1
$1
Credit Risk of going bust: higher than 91% of companies Debt: 60.4% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the riskiest tenth, about 1 in 20 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.21 (down 77%), Allarity Therapeutics, Inc. would be worth roughly what it owes.
Total debt $22.3M against a stock market value of $14.6M.
Distance to default 1.42 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $22.3M (short-term plus half of long-term), stock volatility 76.6%; Altman Z'' -15.37. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.21 (down 77%), Allarity Therapeutics, Inc. would be worth roughly what it owes.
Total debt $22.3M against a stock market value of $14.6M.
Distance to default 1.42 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $22.3M (short-term plus half of long-term), stock volatility 76.6%; Altman Z'' -15.37. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
18 relationships18
As Filer
counterparties named
0
As Counterparty
mentioned by others
4
Rel. Types
2021-12-10
Earliest Filing
2026-01-29
Latest Filing
partner: 9
investor: 7
licensee: 1
target: 1
Counterparties (Filed by ALLR)
18 relationshipsCompanies named in ALLR's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Tumim Stone Capital LLC | — | investor | Entered into a Common Stock Purchase Agreement to potentially purchase up to $6,000,000 of the Company's common stock. | 2026-01-29 | View |
| Eisai Inc. | — | partner | Licensee of exclusive worldwide rights for Stenoparib; entered into Sixth Amendment to extend Phase 2 trial deadline and | 2024-08-21 | View |
| Ascendiant Capital Markets, LLC | — | partner | Entered into an At-The-Market Issuance Sales Agreement to act as agent for the sale of the Company's common stock. | 2024-03-20 | View |
| 3i, LP | TGOPF | investor | Purchased a senior convertible promissory note for $600,000 with conversion rights into common stock. | 2024-03-15 | View |
| 3i, LP | TGOPF | investor | Purchased $400,000 senior convertible promissory note with 8% annual interest and conversion rights. | 2024-02-14 | View |
| 3i, LP | TGOPF | investor | Purchaser in securities purchase agreement amended on January 25, 2024 | 2024-01-25 | View |
| Eisai, Inc. | ELIS | partner | Licensee in an exclusive license agreement for Stenoparib clinical trials | 2023-06-01 | View |
| 3i, LP | TGOPF | investor | Investor holding Series A Preferred Stock and warrants | 2023-06-01 | View |
| 3i, LP | TGOPF | investor | Holder of Series A Convertible Preferred Stock and secured promissory note; entered into letter agreement to modify conv | 2022-12-12 | View |
| Novartis Pharma AG | NVSEF | partner | Licensee in a Second Amendment to License Agreement regarding milestone payments and clinical trial definitions. | 2022-09-30 | View |
| R-Pharm U.S. Operating LLC | — | partner | Partner in a Development, Option & License Agreement amendment to extend clinical development timeline for IXEMPRA. | 2022-08-12 | View |
| 3i, LP | TGOPF | investor | Holder of Series A Preferred Stock and Warrant; party to Forbearance Agreement Amendment. | 2022-06-10 | View |
| Novartis Pharma AG | NVSEF | partner | Licensee in a First Amendment to License Agreement involving a Convertible Promissory Note. | 2022-04-18 | View |
| LiPlasome Pharma ApS | — | partner | Licensee and partner in the amended license agreement for LiPlaCis development | 2022-04-01 | View |
| Chosa ApS | — | partner | New exclusive licensee replacing Allarity Europe in the amended license agreement | 2022-04-01 | View |
| Smerud Medical Research International AS | — | partner | Original sublicensee and party to the support agreement and termination discussions | 2022-04-01 | View |
| Oncoheroes Biosciences, Inc. | — | licensee | Signed exclusive license agreements to acquire global development and commercialization rights for Dovitinib and Stenopa | 2022-01-06 | View |
| Allarity Therapeutics A/S | ALLR | target | Target company in the Recapitalization Share Exchange acquiring assets and liabilities in exchange for Allarity Therapeu | 2021-12-10 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-01 | Other Events; Exhibits | View | |
| 2026-09-29 | Other Events; Exhibits | View | |
| 2026-09-16 | Other Events; Exhibits | View | |
| 2026-09-14 | Other Events; Exhibits | View | |
| 2026-08-14 | Earnings Release; Exhibits | View | |
| 2026-07-01 | Shareholder Vote; Other Events; Exhibits | View | |
| 2026-06-22 | Other Events; Exhibits | View | |
| 2026-06-02 | Officer/Director Change; Exhibits | View | |
| 2026-05-08 | Regulation FD; Other Events; Exhibits | View | |
| 2026-05-06 | Other Events; Exhibits | View | |
| 2026-04-28 | Other Events; Exhibits | View | |
| 2026-04-22 | Other Events; Exhibits | View | |
| 2026-04-01 | Earnings Release; Exhibits | View | |
| 2026-03-09 | Other Events; Financial Statements and Exhibits | View | |
| 2026-03-06 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Financial Stateme | Agreement | View |
| 2026-02-19 | Other Events; Financial Statements and Exhibits | View | |
| 2026-02-04 | Other Events; Financial Statements and Exhibits | View | |
| 2026-01-29 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-12-23 | Unregistered Sales of Equity Securities | View | |
| 2025-12-08 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR